Have any questions? 706-721-6582 or cts@augusta.edu
- NMTRC 014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
Clinical Trial
NMTRC 014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
The purpose of this research study is to evaluate an investigational drug (DFMO) for neuroblastoma that is in remission. This study will look at the ability of the study drug to keep the tumor in remission and will also look at the safety and tolerability of DFMO. DFMO was shown to be effective in inhibiting tumor growth in adult colon cancer and has been tested in multiple adult clinical trials and four pediatric trials. Laboratory testing in neuroblastoma suggests that this drug may be effective in treating this disease.
Eligibility Criteria
- Inclusion*: Less than or equal to 30.99 years of age Diagnosis: High risk neuroblastoma Less than 60 days from last dose of previous therapy Exclusion*: Currently receiving other Investigational drug therapy Infection not under control
RESEARCH. INNOVATION. DISCOVERY.